Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Efficacy and Safety of Anlotinib Combined With Docetaxel in the Treatment of Wild-type Advanced Non-squamous Non Small Cell Lung Cancer Patients With Progress After Immunotherapy Plus Chemotherapy as First-line Treatment

NCT04619537 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT04619537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Efficacy and Safety of Anlotinib Combined With Docetaxel in the Treatment of Wild-type Advanced Non-squamous Non Small Cell Lung Cancer Patients With Progress After Immunotherapy Plus Chemotherapy as First-line Treatment
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 2
Overall status
Unknown status
Start date
October 8, 2020
Completion date
October 31, 2022
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer